Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Apr 5:10:338.
doi: 10.3389/fneur.2019.00338. eCollection 2019.

Neurofilament Light Chain as a Biomarker in Multiple Sclerosis

Kristin N Varhaug  1   2   3 , Øivind Torkildsen  1   2   3 , Kjell-Morten Myhr  1   2   3 , Christian A Vedeler  1   2   3
Affiliations
Review

Neurofilament Light Chain as a Biomarker in Multiple Sclerosis

Kristin N Varhaug et al. Front Neurol. .

Abstract

Due to the unpredictable course and heterogenous treatment response in multiple sclerosis (MS), there is a clear need for biomarkers that reflect disease activity in the clinical follow-up of these patients. Neurofilaments are neuron-specific components of the cytoskeleton that can be assayed in different body compartments. They have been explored as potential biomarkers for many years. Neurofilament light chain (NF-L) appears the most promising biomarker in MS patients, and there is now little doubt that NF-L should have a role in the follow-up of MS patients. Newer assays and techniques for NF-L detection available in serum samples confirms the usefulness of NF-L as a biomarker. Nevertheless, there is still a need for prospective studies, and studies to determine clinical useful cut-off values. This review evaluates the strengths and weaknesses of NF-L as a biomarker in patients with MS.

Keywords: axonal damage; biomarker; cerebrospinal Fluid—CSF; multiple scleorsis (MS); neurofilament light (NF-L); serum.

PubMed Disclaimer

References

    1. Lycke JN, Karlsson JE, Andersen O, Rosengren LE. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry. (1998) 64:402–4. 10.1136/jnnp.64.3.402 - DOI - PMC - PubMed
    1. Cairns NJ, Lee VM, Trojanowski JQ. The cytoskeleton in neurodegenerative diseases. J Pathol. (2004) 204:438–49. 10.1002/path.1650 - DOI - PMC - PubMed
    1. Chevalier-Larsen E, Holzbaur EL. Axonal transport and neurodegenerative disease. Biochim Biophys Acta. (2006) 1762:1094–108. 10.1016/j.bbadis.2006.04.002 - DOI - PubMed
    1. Karlsson JE, Rosengren LE, Haglid KG. Quantitative and qualitative alterations of neuronal and glial intermediate filaments in rat nervous system after exposure to 2,5-hexanedione. J Neurochem. (1991) 57:1437–44. 10.1111/j.1471-4159.1991.tb08311.x - DOI - PubMed
    1. Rosengren LE, Karlsson JE, Karlsson JO, Persson LI, Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. (1996) 67:2013–8. 10.1046/j.1471-4159.1996.67052013.x - DOI - PubMed